Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTHFD2 | P13995 | 2/20 | 0.74 |
| ▸ | MTHFD1 | P11586 | 2/20 | 0.74 |
| ▸ | DHFR | P00374 | 2/20 | 0.61 |
| ▸ | MTR | Q99707 | 1/20 | 0.60 |
| ▸ | GART | P22102 | 6/20 | 0.57 |
| ▸ | SOST | Q9BQB4 | 1/20 | 0.57 |
| ▸ | ATIC | P31939 | 4/20 | 0.56 |
| ▸ | TYMS | P04818 | 1/20 | 0.54 |
| ▸ | FPGS | Q05932 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Folitixorin SCHEMBL4108452 | 1.00 | MTHFD2 (0.74) | MTHFD2MTHFD1DHFRMTRGART | |
| Arfolitixorin SCHEMBL29616436 | 1.00 | MTHFD2 (0.74) | MTHFD2MTHFD1DHFRMTRGART | |
| Arfolitixorin SCHEMBL186747 | 1.00 | MTHFD2 (0.74) | MTHFD2MTHFD1DHFRMTRGART | |
| Folitixorin SCHEMBL16467076 | 1.00 | MTHFD2 (0.74) | MTHFD2MTHFD1DHFRMTRGART | |
| Folitixorin SCHEMBL258730 | 1.00 | MTHFD2 (0.74) | MTHFD2MTHFD1DHFRMTRGART | |
| Folitixorin SCHEMBL3180668 | 1.00 | MTHFD2 (0.74) | MTHFD2MTHFD1DHFRMTRGART | |
| Folitixorin SCHEMBL4537420 | 0.99 | MTHFD2 (0.73) | MTHFD2MTHFD1DHFRMTRGART | |
| Arfolitixorin SCHEMBL30694324 | 0.99 | MTHFD2 (0.73) | MTHFD2MTHFD1DHFRMTRGART | |
| Folitixorin SCHEMBL29556725 | 0.98 | MTHFD2 (0.72) | MTHFD2MTHFD1DHFRMTRGART | |
| Folitixorin SCHEMBL9430909 | 0.97 | MTHFD2 (0.70) | MTHFD2MTHFD1DHFRMTRGART |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3480 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125722-A1 | METHOD FOR PRODUCING METHYL COMPOUND | MITSUBISHI CHEMICAL CORPORATION (JP) | 2026-05-07 | — | — | US | claimed |
| EP-4688828-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOUND FOR DIAGNOSIS AND/OR THERAPEUTIC USES THEREOF | Jubilant DraxImage Inc. (CA) | 2026-02-11 | — | — | EP | claimed |
| EP-4692361-A1 | METHOD FOR PRODUCING METHYL COMPOUND | Mitsubishi Chemical Corporation (JP) | 2026-02-11 | — | — | EP | claimed |
| EP-4692363-A1 | METHOD FOR PRODUCING METHYL COMPOUND | Mitsubishi Chemical Corporation (JP) | 2026-02-11 | — | — | EP | claimed |
| US-20240415837-A1 | PHARMACOLOGIC MODULATION OF 5-FLUOROURACIL BY FOLINIC ACID AND VITAMIN B6 FOR THE TREATMENT OF PATIENTS WITH CARCINOMA | MACHOVER DAVID (FR) | 2024-12-19 | — | — | US | claimed |
| US-20240392332-A1 | Cell Free-Based Biocatalyst for Formate Conversion into Value-Added Chemicals | BATTELLE MEMORIAL INSTITUTE (FOR MANAGEMENT AND OPERATION OF PACIFIC NORTHWEST NATIONAL LABORATORY) | 2024-11-28 | — | — | US | claimed |
| US-20240358843-A1 | LIGAND-DRUG CONJUGATE AND USE THEREOF | COHERENT BIOPHARMA SUZHOU LTD (CN) | 2024-10-31 | — | — | US | claimed |
| WO-2024204791-A1 | METHOD FOR PRODUCING METHYL COMPOUND | 三菱ケミカル株式会社 | 2024-10-03 | — | — | WO | claimed |
| WO-2024204792-A1 | METHOD FOR PRODUCING METHYL COMPOUND | 三菱ケミカル株式会社 | 2024-10-03 | — | — | WO | claimed |
| WO-2024201255-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOUND FOR DIAGNOSIS AND/OR THERAPEUTIC USES THEREOF | JUBILANT DRAXIMAGE INC. (CA) | 2024-10-03 | — | — | WO | claimed |
| US-5455236-A | Stable aqueous compositions | EPROVA AKTIENGESELLSCHAFT (CH) | 1995-10-03 | — | — | US | claimed |
| EP-0495204-B1 | Process for the preparation of (6S)- and (6R)-tetrahydrofolic acid | EPROVA AG (CH) | 1995-06-14 | — | — | EP | claimed |
| EP-0537492-B1 | Stable salts of 5,10-methylenetetrahydrofolic acid | EPROVA AG (CH) | 1995-05-17 | — | — | EP | claimed |
| EP-0579996-B1 | Inclusion compounds of 5,10-methylenetetrahydrofolic acid and cyclodextrin | EPROVA AG (CH) | 1995-05-03 | — | — | EP | claimed |
| EP-0579996-A1 | Inclusion compounds of 5,10-methylenetetrahydrofolic acid and cyclodextrin | EPROVA Aktiengesellschaft (CH) | 1994-01-26 | — | — | EP | claimed |
| EP-0539987-A2 | Process for the purification of crude alkalinic earth metal salts of N(5)-methyl-5,6,7,8-tetrahydrofolic acid | Cerbios-Pharma S.A. (CH) | 1993-05-05 | — | — | EP | claimed |
| EP-0537492-A2 | Stable salts of 5,10-methylenetetrahydrofolic acid | EPROVA Aktiengesellschaft (CH) | 1993-04-21 | — | — | EP | claimed |
| EP-0495204-A1 | Process for the preparation of (6S)- and (6R)-tetrahydrofolic acid | EPROVA Aktiengesellschaft (CH) | 1992-07-22 | — | — | EP | claimed |
| WO-1992002241-A1 | A PROCESS OF MAKING TETRAHYDROPTEROYLPOLY-L-GLUTAMIC ACID DERIVATIVES | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, UNITED STATES DEPARTMENT OF COMMERCE (US) | 1992-02-20 | — | — | WO | claimed |
| WO-1991017660-A1 | 5,10-METHYLENE-TETRAHYDROFOLATE AS A MODULATOR OF A CHEMOTHERAPEUTIC AGENT | SPEARS COLIN P (US) | 1991-11-28 | — | — | WO | claimed |